Amivantamab

About

Therapy type: Targeted therapy

Therapy strategy: EGFR inhibition

Mappings

NCI Thesaurus: Amivantamab (ncit:C124993)

View API

Therapeutic response

Precision oncology relationships for therapeutic response involving this therapy.

Type Biomarker(s) Cancer type Therapy(ies)
Sensitivity (+) EGFR Exon 20 (Insertion) Non-Small Cell Lung Cancer Amivantamab, Carboplatin, Pemetrexed FDA
Sensitivity (+) EGFR Exon 20 (Insertion) Non-Small Cell Lung Cancer Amivantamab FDA
Sensitivity (+) EGFR Exon 19 (Deletion) Non-Small Cell Lung Cancer Amivantamab, Lazertinib FDA
Sensitivity (+) EGFR p.L858R Non-Small Cell Lung Cancer Amivantamab, Lazertinib FDA
Sensitivity (+) EGFR Exon 19 (Deletion) Non-Small Cell Lung Cancer Amivantamab, Lazertinib FDA
Sensitivity (+) EGFR p.L858R Non-Small Cell Lung Cancer Amivantamab, Lazertinib FDA
Sensitivity (+) EGFR Exon 19 (Deletion) Non-Small Cell Lung Cancer Amivantamab, Carboplatin, Pemetrexed FDA
Sensitivity (+) EGFR p.L858R Non-Small Cell Lung Cancer Amivantamab, Carboplatin, Pemetrexed FDA
Sensitivity (+) EGFR Exon 19 (Deletion) Non-Small Cell Lung Cancer Amivantamab, Lazertinib HC
Sensitivity (+) EGFR p.L858R Non-Small Cell Lung Cancer Amivantamab, Lazertinib HC
Sensitivity (+) EGFR Exon 19 (Deletion) Non-Small Cell Lung Cancer Amivantamab, Carboplatin, Pemetrexed HC
Sensitivity (+) EGFR p.L858R Non-Small Cell Lung Cancer Amivantamab, Carboplatin, Pemetrexed HC
Sensitivity (+) EGFR Exon 20 (Insertion) Non-Small Cell Lung Cancer Amivantamab, Carboplatin, Pemetrexed HC
Sensitivity (+) EGFR Exon 20 (Insertion) Non-Small Cell Lung Cancer Amivantamab HC